Pharmaceuticals Market Research Reports & Industry Analysis

... by kidney and liver that stimulates erythropoiesis. Indications of EOP approved in China are renal anemia, anemia after chemotherapy and surgery perioperative ... space for EPO used in anemia after chemotherapy in China. Originally developed by Amgen Inc., epoetin alfa was approved to the U.S. in June 1989 by ...

... approved to China in 2002 to treat CML and GIST. Its market size keeps increasing after its launch. According to CRI's investigation on sample ... Hospital Market Incidence of CML in China Manufacturing Schedule of Imatinib Generic Drug Prospect of China Imatinib Market The following enterprises and people ...

... the end of 2013 there have been over 10 million schizophrenia patients in China, and the number is still increasing year after year. Schizophrenia ... in Different Dosage Forms in China Hospital Market Prospect of China Aripiprazole Market The following enterprises and people are recommended to purchase this ...

... promising. “HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights: Introduction to HIV Vaccine & Mechanism Global HIV Incidence Scenario R&D Funding Scenario for HIV Vaccine FDA Regulatory Framework HIV Vaccine Clinical Trial by Phase & Country HIV Vaccines in Development Phase ...

... threatening diseases. “Global Cell Therapy Market & Pipeline Insight” Report Highlights & Findings: Introduction to Cell therapy Global Cell Therapy Market Overview Global Cell Therapy Market Dynamics Cell Therapy Pipeline by Phase, Country & Target Indications Cell Therapy Drugs in Pipeline: More ...

... , and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have ... Market Production Status of Enoxaparin Sodium Generic Drug in China Major Enoxaparin Sodium Manufacturers in China Prospect of China Enoxaparin Sodium Market The ...

... value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only ... China Hospital Market Incidence of Cancer in China Manufacturing Schedule of Pemetrexed generic drug Prospect of China Pemetrexed Market The following enterprises and people ...

... benchmarking research studying the cost structure of Chinese vitamin C and the competitiveness of major Chinese players. ... set up the model and verify afterwards. The breakeven price of Chinese products is concluded. The aim of ... as how to penetrate the ever-increasing China market and how to catch the maximum ...

... remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the ... Dosage Forms in Hospital Market in China Incidence of Cancer in China Manufacturing Schedule of Bevacizumab generic drug Prospect of China Bevacizumab Market The author ...

... increasing, which nearly reached USD 5 billion in 2012. The success of duloxetine sales also comes from its persistent exploration and study ... in Different Dosage Forms in China Hospital Market Prospect of China Duloxetine Market The author recommends the report to the following: Antidepressant APIs ...

... pharma companies truly integrating health outcome values into product development or merely paying lip-service? In a rare and comprehensive insight into thriving in the "Outcomes Era", Value-driven Pharma: Integrating health outcomes across ... been shaped by economics. In Value-driven Pharma: Integrating health outcomes across the product lifecycle, you will: Understand the importance of endorsing a comprehensive approach to health outcomes from the earliest ...

... all of the ‘low hanging fruit’ have been taken there is another perspective: that there is plenty of fruit left on the tree and companies ... company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment ...

... can acquire the following information: Market Share of Major Valsartan Manufacturers in Sampling Hospitals in China Sales price of valsartan in hospital market in China Major valsartan enterprises in China Market share of valsartan by dosage form in hospital market in China Prospect of China valsartan ...

... orphan drugs. “Europe Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to Europe orphan drug market: Europe Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework Europe ...

... . “US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market: US Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework US Orphan Drug ...

... . “Global Radiopharmaceuticals Market Insight” Report Highlights Global Radio Pharmaceuticals Market Overview by Region arget Patient Base by Region Radiopharmaceuticals Market Regulation for US, Europe & Canada Radioisotopes Used in Radiopharmaceuticals Radiopharmaceutical Clinical Pipeline Insight ...

In the US, a third party administrator of prescription drug program is known as a Pharmacy Benefit Manager (PBM). The primary responsibilities of a PBM include processing and paying ...

... that address the unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these ... sluggish pace of innovation and inappropriate use of therapeutic drugs. The specialty pharmaceutical market witnesses fierce competition with numerous top notch players; such ...

... in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2013: Rising Stars

... by pharma companies in India. Our outlook 2014 on India Pharma covers overall business and market growth for Indian companies, ParaIV filing, NCE pipeline and biosimilar and NDDS development ...

... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...

... : NHI price cut, Japan generic opportunity, Prograf, Xtandi, Isavuconazole, Myrbetriq, Astellas, Chugai, Actemra, Perjeta, biosimilar, Kadcyla, breast cancer, prostate cancer, MPDL3280A, Daiichi Sankyo, Edoxaban , Ranbaxy, Dainnipon Sumitomo, Dainnipon, cancer stem cell inhibitor, BBI-608, Latuda, DS-3025 ...

... melanoma and breast cancer from major pharmaceutical companies. Many of them are ... high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will ... repurchase program and dividend policy. Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors ...

... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , controls, calibrators and others. “2014 Analysis of the Global Drugs of Abuse Testing Market” is a unique study designed to help current suppliers and ...

... : Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/ Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva ...

... / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase: Research: 19 Preclinical: 49 Clinical: 1 Phase-I: 25 Phase-I/II: 2 Phase-II: 26 Phase-II/III: 2 Phase-III: 5 Preregistration: 2 Marketed: 10 Unknown: 1

... for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close ... cancer every year, this market is expected to o reach USD 20 billion by 2020. “US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...

... for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Parkinson’s Disease Drug Pipeline by Clinical Phase: Research: 12 Clinical: 26 Phase-I: 14 Phase-I/II: 2 Phase-II: 6 Phase-II/III: 1 Phase-III: 3 Preregistration: 1 Marketed: 18

... Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Number of Skin Cancer Drug in Pipeline by Clinical Phase: Research: 3 Preclinical: 29 Clinical: 5 Phase 0: 1 Phase-I: 29 Phase-I/II: 18 Phase-II: 41 Phase-III: 13 Registered: 4 Marketed: 18 Unknown: 1

... for the pharma companies in their every-day decision making. “Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process. Following parameters for ...

... identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process. Following parameters for ... drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...

... in the Europe orphan designated drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report: Drug Profile Overview Active Indication ...

... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...

... is changing. In Designing Clinical Trials to Show Value, you will: Understand how new concepts of value created by cost-conscious healthcare stakeholders are transforming clinical development programmes ... Understand new trends in clinical trials that promise to deliver product value sought by regulators, health systems and patients Designing Clinical Trials to Show Value answers key questions ...

... . This report breaks down KAM requirements and lets you build the team you need. This new report Effective Pharma KAM Teams – the essential factors driving performance provides everyone involved with building running or implementing KAM ...

... pace of growth is not being reported in the area of development of drugs and therapies for treating cancers. The report also predicts that the ... analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with ...

The 2014 U.S. Medical Equipment & Supplies Mfg. Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry ... , inventories, rentals, and other expenses nationally and for all 50 U.S. States and up to 900 metro areas. Expenses categories include materials used ...

The 2014 U.S. Pharmaceutical Preparation Mfg. Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, ...

The 2014 U.S. Pharmacies & Drug Stores Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, ...

... Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical ... also received clinical approval issued by SFDA in September 2013. Global and China Insulin Industry Report, 2013-2017 mainly covers the ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

... (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points ... Alliances in Alzheimer’s Disease Drug Market B. Licensing Agreement in Alzheimer’s Disease Drug Market C. Collaboration Deal in Alzheimer’s Disease Drug Market D. Merger & Acquisition ...

... and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the ... . The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical ...

... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...

... players will continue to boost the market. According to our report, “Russian Pharmaceutical Market Outlook to 2017”, the pharmaceutical market is anticipated to grow at a CAGR ... focuses on the emerging pharmaceutical clusters in Russia and the role they will play in shaping the market. The market has been ...